Atox Bio has been granted orphan drug designation by US Food and Drug Administration (FDA) for AB103, used to treat necrotising soft tissue infections.

AB103 is a short peptide that acts as a CD28 modulator, regulating the inflammatory response in the host.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The drug candidate has completed a Phase I study and expects to go into a Phase II proof-of-concept study to assess its clinical benefit.

Atox Bio CEO Dan Teleman said, "The FDA’s decision to grant AB103 orphan drug designation is another important milestone for our clinical program and underscores the urgency of the need for new treatments for this life threatening infection."

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact